LFA
ALXN

Legacy Financial Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Legacy Financial Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-31
Closed -$4K – 1004
2019
Q1 		$4K Buy
31
+26
+520% +$3.23K ﹤0.01% 834
2018
Q4 		$0 Sell
5
-82
-94% -$9.69K ﹤0.01% 1067
2018
Q3 		$12K Hold
87
– – ﹤0.01% 483
2018
Q2 		$12K Buy
87
+11
+14% +$1.29K ﹤0.01% 484
2018
Q1 		$8K Buy
76
+71
+1,420% +$8.49K ﹤0.01% 554
2017
Q4 		$0 Buy
+5
New +$609 ﹤0.01% 870

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Legacy Financial Advisors's ALXN Position: Q2 2019 in Review

Legacy Financial Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 31 shares — an estimated $4K sold.

Legacy Financial Advisors first reported a position in ALXN in Q4 2017 and held it in 6 quarters. The position peaked at $12K in Q3 2018. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

  • Legacy Financial Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Legacy Financial Advisors sold 31 Alexion Pharmaceuticals shares in Q2 2019, an estimated $4K.
  • Legacy Financial Advisors first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 6 quarters.
  • Legacy Financial Advisors's Alexion Pharmaceuticals position peaked at $12K in Q3 2018.
  • 636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on Legacy Financial Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.